Drugs / Atherolive
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 2/3 | NCT06723002 Comparator | Dec 2024 → Dec 2025 overdue | acute coronary syndrome | University of Monastir | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05636826 Comparator | Dec 2023 → Nov 2024 | hypertensive disorder | University of Monastir | Completed | No outcome recorded |
| Phase 2/3 | NCT05605704 Comparator | Jan 2023 → Sep 2025 overdue | type 2 diabetes mellitus | University of Monastir | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05297110 Comparator | Aug 2021 → Nov 2023 | hypertensive disorder, type 2 diabetes mellitus | University of Monastir | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atherolive | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05636826 ↗ |
| Known as | olive leaf extracts | “study drug (olive leaf extracts) which will be prescribed at dose of 250 mg” NCT06723002 ↗ |